Patients' perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy.
Vicky MaiCamille GosselinÉlodie TremblayGabrielle RompréAnnie Christine LajoieJason WeatheraldJean-Christophe LegaSébastien BonnetSteeve ProvencherPublished in: Thorax (2023)
The value placed by patients and their caregivers on the components of composite outcomes in pulmonary arterial hypertension (PAH) remains unknown. We surveyed the importance of these outcomes from a patients' and caregivers' perspective, with participants (n=335, including 257 patients with PAH) rating individual components defining clinical worsening in PAH trials as of critical, major, mild-to-moderate or minor importance. Most outcomes were considered of major or mild-to-moderate importance to patients. Death was the only outcome considered of critical importance. Perceptions of clinical outcomes varied between patients and caregivers. Integrating patients' perception in the elaboration of clinical trials is essential.
Keyphrases
- end stage renal disease
- pulmonary arterial hypertension
- newly diagnosed
- chronic kidney disease
- ejection fraction
- primary care
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- pulmonary artery
- healthcare
- stem cells
- type diabetes
- skeletal muscle
- pulmonary hypertension
- coronary artery
- insulin resistance
- mesenchymal stem cells
- patient reported
- smoking cessation
- cell therapy
- phase ii
- weight loss